Corporate Venture Capital - An Alternative Route To Finance?
The buzz around the biopharma industry is that the traditional venture capital (VC) companies are withdrawing from funding new pharma and biotech start-ups in favor of supporting their existing portfolio companies. Coupling this with the lack of IPOs during 2008 and 2009, this leaves a large funding void at the early-stage part of the industry.
